CDK6-IN-2
CDK6-IN-2 is a CDK6 covalent inhibitor with an IC50 of 0.013 μM. CDK6-IN-2 inhibits the proliferation and migration of triple-negative breast cancer cells, and induces cell cycle arrest and apoptosis. CDK6-IN-2 induces ROS accumulation and mitochondrial damage through cellular metabolic reprogramming. CDK6-IN-2 exhibits anti-tumor activity and can be used for the research of triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C24H29BrN6O3
- Molecular Weight:529.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK6 0.013 μM (IC50) |
Caspase 3 |
In Vitro
CDK6-IN-2 (compound C32) (72 h) selectively inhibits the viability of TNBC and BRCA1-mutant breast cancer cells with an IC50 value ≤ 0.08 μM, while exhibits low activity against normal mammary epithelial cells and ER-positive breast cancer cells[1].
CDK6-IN-2 (0-0.2 μM; 0-72 h) potently inhibits the proliferation and migration of MDA-MB-231 and BT-549 triple-negative breast cancer (TNBC) cells, and induces apoptosis, cell cycle arrest, and intracellular ROS accumulation[1].
CDK6-IN-2 (0-0.20 μM; 72 h) induces mitochondrial damage and dysfunction, including reduced membrane potential and structural abnormalities, in MDA-MB-231 and BT-549 triple-negative breast cancer (TNBC) cells[1].
CDK6-IN-2 (0-0.20 μM; 72 h) inhibits autophagic flux and degradation processes in MDA-MB-231 and BT-549 triple-negative breast cancer (TNBC) cells, which is evidenced by the co-accumulation of LC3II and P62 proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Triple-negative breast cancer (TNBC) lines MDA-MB-231, MDA-MB-468, BT-549; BRCA1-mutant line MDA-MB-436; ER-positive line MCF-7; normal mammary epithelial line MCF-10A
-
Concentration:/
-
Incubation Time:72 h
-
Result:Selectively inhibited the viability of TNBC and BRCA1-mutant breast cancer cells with IC50 values of 0.06 μM (MDA-MB-231), 0.08 μM (MDA-MB-468), 0.04 μM (BT-549), and 0.06 μM (MDA-MB-436).
Showed reduced activity against non-TNBC cells with IC50 = 0.39 μM (MCF-7), 2.30 μM (MCF-10A).
-
Cell Line:TNBC cell lines MDA-MB-231 and BT-549
-
Concentration:MDA-MB-231: 0.1, 0.15, 0.2 μM; BT-549: 0.08, 0.12, 0.16 μM
-
Incubation Time:72 h
-
Result:Concentration-dependently reduced the number of EdU-positive proliferating cells in both TNBC lines.
-
Cell Line:TNBC cell line MDA-MB-231
-
Concentration:0.10, 0.15, 0.20 μM
-
Incubation Time:72 h
-
Result:Induced a concentration-dependent S-phase cell cycle arrest, with the proportion of S-phase cells increasing from 35.91% (control) to 40.68% (0.10 μM), 48.31% (0.15 μM), and 55.9% (0.20 μM), while the proportion of G0/G1-phase cells decreased correspondingly.
Parmacokinetics
| Species | Dose | Route | C0 | AUC0-t | AUC0-∞ | T1/2 | Vd/F | CL/F |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 2 mg/kg | i.v. | 772.60 ng/mL | 82.75 ng·h/mL | 93.80 ng·h/mL | 0.59 h | 13.09 L/kg | 15.46 L/h/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 4 weeks old, subcutaneous inoculation of 1×107 MDA-MB-231 cells)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily; 18 days
-
Result:Reduced mean tumor weight to 0.68 g (10 mg/kg group) and 0.23 g (20 mg/kg group), significantly lower than the control group's 1.45 g.
Significantly down-regulated Ki67, CDK6, and RB1 positive cell counts in treated tumor tissues.
Significantly up-regulated Cleaved Caspase-3 positive cell counts in treated tumor tissues.
Caused no significant changes in mouse body weight.
Showed no pathological damage to major organs (heart, liver, spleen, lung, kidney) via H&E staining.
Chemical Information
-
Molecular Weight 529.43
-
Formula C24H29BrN6O3
-
SMILES
C#CC(NC(C)C(N1CCC(NC2=NC=C(C(C)=C(Br)C(N3C4CCCC4)=O)C3=N2)CC1)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)